CGTX COGNITION THERAPEUTICS INC US FDA Inspections 8-K Filing 2025 - Clinical Trials On May 8, 2025, Cognition Therapeutics, Inc. announced the topline results from its Phase 2 clinical trial, COG2201, for zervimesine aimed at treating geographic atrophy due to dry age-related macular degeneration.Get access to all SEC 8-K filings of the COGNITION THERAPEUTICS INC